臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

關於TAIR
	計畫說明

瀏覽
	典藏機構
	作者
	題名
	日期
	統計圖表
	機構即時統計
	學術趨勢

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作權
	出版社及期刊政策查詢
	TAIR著作權會議記錄

相關連結
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"tseng t c"的相關文件

回到依作者瀏覽
依題名排序	依日期排序

顯示項目 176-225 / 534 (共11頁)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目

機構	日期	題名	作者
臺大學術典藏	2021-09-04T06:11:35Z	What can we learn from hepatitis B virus clinical cohorts?	Lin C.-L.; Tseng T.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:35Z	Hepatitis B virus infection and metabolic syndrome: Fact or fiction?	Wang C.-C.; Tseng T.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:34Z	Treating immune-tolerant Hepatitis B	Tseng T.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:34Z	Micro-evolution of the hepatitis B virus genome in hepatitis B e-antigen-positive carriers: Comparison of genotypes B and C at various immune stages	Liu C.-J.; Chen T.-C.; Chen P.-J.; Wang H.-Y.; Tseng T.-C.; Cheng H.-R.; Liu C.-H.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:31Z	Fibrosis index based on four factors better predicts advanced fibrosis or cirrhosis than aspartate aminotransferase/platelet ratio index in chronic hepatitis C patients	Wang C.-C.; Liu C.-H.; Lin C.-L.; Wang P.-C.; Tseng T.-C.; Lin H.H.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:30Z	Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection	Cheng H.-R.; JIA-HORNG KAO; Wu H.-L.; Tseng T.-C.; Liu C.-H.; Yang H.-C.; Su T.-H.; Chen P.-J.; Chen D.-S.; Liu C.-J.
臺大學術典藏	2021-09-04T06:11:29Z	Treating Immune-tolerant Hepatitis B	Tseng, T.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:28Z	Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection	Hsu C.-S.; Liu W.-L.; Chao Y.-C.; Lin H.H.; Tseng T.-C.; Wang C.-C.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:28Z	HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients	Peng C.-Y.; Hsieh T.-C.; Hsieh T.-Y.; Tseng K.-C.; Lin C.-L.; Su T.-H.; Tseng T.-C.; Lin H.H.; Wang C.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:27Z	Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection	Tseng T.-C.; Liu C.-J.; Chen C.-L.; Yang W.-T.; Yang H.-C.; Su T.-H.; Wang C.-C.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:26Z	Predicting hepatitis B virus (HBV) surface antigen seroclearance in HBV e antigen-negative patients with chronic hepatitis B: External validation of a scoring system	Liu J.; Tseng T.-C.; Yang H.-I.; Lee M.-H.; Batrla-Utermann R.; Jen C.-L.; Lu S.-N.; Wang L.-Y.; You S.-L.; Chen P.-J.; Chen C.-J.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:25Z	Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition	Su T.-H.; Shiau C.-W.; Jao P.; Liu C.-H.; Liu C.-J.; Tai W.-T.; Jeng Y.-M.; Yang H.-C.; Tseng T.-C.; Huang H.-P.; Cheng H.-R.; Chen P.-J.; Chen K.-F.; JIA-HORNG KAO; Chen D.-S.
臺大學術典藏	2021-09-04T06:11:23Z	Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers	Tseng T.-C.; Liu C.-J.; Yang H.-C.; Chen C.-L.; Yang W.-T.; Tsai C.-S.; Kuo S.F.-T.; Verbree F.C.; Su T.-H.; Wang C.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:20Z	Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis	Yang H.-I.; Tseng T.-C.; Liu J.; Lee M.-H.; Liu C.-J.; Su T.-H.; Batrla-Utermann R.; Chan H.L.Y.; JIA-HORNG KAO; Chen C.-J.
臺大學術典藏	2021-09-04T06:11:18Z	Hepatitis C viral infection increases the risk of lymphoid-neoplasms: A population-based cohort study	Su T.-H.; Liu C.-J.; Tseng T.-C.; Chou S.-W.; Liu C.-H.; Yang H.-C.; Wu S.-J.; Chen P.-J.; Chen D.-S.; Chen C.-L.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:17Z	Hepatitis B surface antigen loss and hepatocellular carcinoma development in patients with dual hepatitis B and C infection	Yang W.-T.; Wu L.-W.; Tseng T.-C.; Chen C.-L.; Yang H.-C.; Su T.-H.; Wang C.-C.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Liu C.-J.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:16Z	Perspectives on dual hepatitis B and C infection in Taiwan	Liu C.-J.; Chen P.-J.; Chen D.-S.; Tseng T.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:15Z	Efficacy of entecavir therapy for hepatitis B e-antigen positive chronic hepatitis B patients with prior exposure to interferon or nucleoside/nucleotide analogues	Tseng K.-C.; Tseng C.-W.; Hsieh T.-Y.; Peng C.-Y.; Lin C.-L.; Su T.-H.; Tseng T.-C.; Lin H.H.; Wang C.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:13Z	Assessing the Durability of Entecavir-Treated Hepatitis B Using Quantitative HBsAg	Wang C.-C.; Tseng K.-C.; Hsieh T.-Y.; Tseng T.-C.; Lin H.H.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:09Z	Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C	Mah Y.-H.; Liu C.-H.; Chen C.-L.; Tseng T.-C.; Liu C.-J.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:08Z	Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients	Su T.-H.; Hu T.-H.; Chen C.-Y.; Huang Y.-H.; Chuang W.-L.; Lin C.-C.; Wang C.-C.; Su W.-W.; Chen M.-Y.; Peng C.-Y.; Chien R.-N.; Huang Y.-W.; Wang H.-Y.; Lin C.-L.; Yang S.-S.; Chen T.-M.; Mo L.-R.; Hsu S.-J.; Tseng K.-C.; Hsieh T.-Y.; Suk F.-M.; Hu C.-T.; Bair M.-J.; Liang C.-C.; Lei Y.-C.; Tseng T.-C.; Chen C.-L.; JIA-HORNG KAO; the C-TEAM study group; the Taiwan Liver Diseases Consortium
臺大學術典藏	2021-09-04T06:11:03Z	Elimination of Hepatitis B: Is It a Mission Possible?	Tseng T.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:01Z	HBV markers for HCC prediction: Three heads are better than two?	Tseng T.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:11:01Z	More viral mutants, less HBsAg clearance? One size may not fit all	Tseng T.-C.; Yang H.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:10:59Z	Fibrosis-4 Index Helps Identify HBV Carriers with the Lowest Risk of Hepatocellular Carcinoma	Tseng T.-C.; Liu C.-J.; Su T.-H.; Yang W.-T.; Chen C.-L.; Yang H.-C.; Wang C.-C.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:10:59Z	Impact of occult hepatitis B on the clinical outcomes of patients with chronic hepatitis C virus infection: A 10-year follow-up	Chen H.-Y.; Su T.-H.; Tseng T.-C.; Yang W.-T.; Chen T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO; Liu C.-J.
臺大學術典藏	2021-09-04T06:10:55Z	Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis	Su T.-H.; Shiau C.-W.; Jao P.; Yang N.-J.; Tai W.-T.; Liu C.-J.; Tseng T.-C.; Yang H.-C.; Liu C.-H.; Huang K.-W.; Hu T.-C.; Huang Y.-J.; Wu Y.-M.; Chen L.-J.; Chen P.-J.; Chen D.-S.; Chen K.-F.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:10Z	Hepatitis b virus–specific t cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation	Rivino L.; Le Bert N.; Gill U.S.; Kunasegaran K.; Cheng Y.; Tan D.Z.M.; Becht E.; Hansi N.K.; Foster G.R.; Su T.-H.; Tseng T.-C.; Lim S.G.; JIA-HORNG KAO; Newell E.W.; Kennedy P.T.F.; Bertoletti A.
臺大學術典藏	2021-09-04T05:17:09Z	Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan	Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:08Z	HCC risk in patients with HBV-related cirrhosis receiving nucleos(t)ide analogues therapy: Is HCC prevented or delayed?	Su T.-H.; Tseng T.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:08Z	Distinct Relapse Rates and Risk Predictors after Discontinuing Tenofovir and Entecavir Therapy	Su T.-H.; Yang H.-C.; Tseng T.-C.; Liou J.-M.; Liu C.-H.; Chen C.-L.; Chen P.-J.; Chen D.-S.; Liu C.-J.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:07Z	Fibrosis-4 index predicts cirrhosis risk and liver-related mortality in 2075 patients with chronic HBV infection	Tseng T.-C.; Liu C.-J.; Su T.-H.; Yang W.-T.; Chen C.-L.; Yang H.-C.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:06Z	Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection	Liu C.-H.; Sun H.-Y.; Liu C.-J.; Sheng W.-H.; Hsieh S.-M.; Lo Y.-C.; Liu W.-C.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:05Z	Acoustic radiation force impulse US imaging: Liver stiffness in patients with chronic hepatitis B with and without antiviral therapy	Su T.-H.; Liao C.-H.; Liu C.-H.; Huang K.-W.; Tseng T.-C.; Yang H.-C.; Liu C.-J.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:03Z	Quantification of serum hepatitis B core antibody to predict off-entecavir relapse in patients with chronic hepatitis B	Tseng C.-H.; Hsu Y.-C.; Chang C.-Y.; Tseng T.-C.; Wu M.-S.; Lin J.-T.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:00Z	Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study	Liu C.-H.; Huang Y.-J.; Yang S.-S.; Chang C.-H.; Yang S.-S.; Sun H.-Y.; Liu C.-J.; Liu W.-C.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:58Z	A novel spontaneous hepatocellular carcinoma mouse model for studying T-cell exhaustion in the tumor microenvironment	Liu Y.-T.; Tseng T.-C.; Soong R.-S.; Peng C.-Y.; Cheng Y.-H.; Huang S.-F.; Chuang T.-H.; JIA-HORNG KAO; Huang L.-R.
臺大學術典藏	2021-09-04T05:16:58Z	Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan	Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:55Z	Large and middle hepatitis B surface antigen: The lower the better?	Lin H.-H.; Tseng T.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:55Z	Profile and value of FIB-4 in patients with dual chronic hepatitis C and B	Liu C.-J.; Tseng T.-C.; Yang W.-T.; Su T.-H.; Yang H.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:54Z	Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection	Su T.-H.; Liu C.-J.; Tseng T.-C.; Chou S.-W.; Liu C.-H.; Yang H.-C.; Wu S.-J.; Chen P.-J.; Chen D.-S.; Chen C.-L.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:54Z	Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis	Yeo Y.H.; Ho H.J.; Yang H.-I.; Tseng T.-C.; Hosaka T.; Trinh H.N.; Kwak M.-S.; Park Y.M.; Fung J.Y.Y.; Buti M.; Rodr?guez M.; Treeprasertsuk S.; Preda C.M.; Ungtrakul T.; Charatcharoenwitthaya P.; Li X.; Li J.; Zhang J.; Le M.H.; Wei B.; Zou B.; Le A.; Jeong D.; Chien N.; Kam L.; Lee C.-C.; Riveiro-Barciela M.; Istratescu D.; Sriprayoon T.; Chong Y.; Tanwandee T.; Kobayashi M.; Suzuki F.; Yuen M.-F.; Lee H.-S.; JIA-HORNG KAO; Lok A.S.; Wu C.-Y.; Nguyen M.H.
臺大學術典藏	2021-09-04T05:16:53Z	Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin's lymphoma and multiple myeloma	Su T.-H.; Liu C.-J.; Tseng T.-C.; Chou S.-W.; Liu C.-H.; Yang H.-C.; Wu S.-J.; Chen P.-J.; Chen D.-S.; Chen C.-L.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:48Z	Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection	Liu C.-H.; Su T.-H.; Liu C.-J.; Hong C.-M.; Yang H.-C.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:46Z	NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging	Su T.-H.; Liao S.-H.; Hong C.-M.; Liu C.-J.; Tseng T.-C.; Liu C.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chen C.-L.; Adhoute X.; Bourli?re M.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:45Z	Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism	Su T.-H.; Yang H.-C.; Tseng T.-C.; Chou S.-W.; Lin C.-H.; Liu C.-H.; Liu C.-J.; Chen C.-L.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:45Z	High Level of Hepatitis B Core–Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load	Tseng T.-C.; Liu C.-J.; Hsu C.-Y.; Hong C.-M.; Su T.-H.; Yang W.-T.; Chen C.-L.; Yang H.-C.; Huang Y.-T.; Fang-Tzu Kuo S.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:41Z	Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis	Su T.-H.; Peng C.-Y.; Tseng T.-C.; Yang H.-C.; Liu C.-J.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:40Z	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan	Liu C.-H.; Liu C.-J.; Hung C.-C.; Hsieh S.-M.; Su T.-H.; Sun H.-Y.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:40Z	Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients	Hsu S.-J.; Enkhzaya S.; Lin Y.-Y.; Tseng T.-C.; Khosbayar T.; Tsai C.-H.; Wang T.-S.; Enkhtuya D.; Ivshinkhorol D.; Naranzul N.; Jargalsaikhan B.; Amarsanaa J.; Baatarkhuu O.; JIA-HORNG KAO

顯示項目 176-225 / 534 (共11頁)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目

	English \| 正體中文 \| 简体中文 \| 總筆數 :2851812
	造訪人次 : 44811720 線上人數 : 1508 教育部委託研究計畫計畫執行:國立臺灣大學圖書館